Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1141)	6/8/2003 5:56:03 PM
From: Miljenko Zuanic	Respond to of 1834

Erik, Yes Provigil and Estorra fit well together, but Estorra will not be cheap. Regards the PFE, I think that street overextended their marketing organs. How they are selling Geodon, or some other me-too drug? Miljenko [eom]

To: Icebrg who wrote (1141)	6/9/2003 6:05:50 PM
From: Icebrg	Read Replies (1) \| Respond to of 1834

Neurocrine Biosciences "buy," target price raised -update [Not that it seems to have helped much today with the stockprice down 6% to something 53-ish] Monday, June 09, 2003 2:51:49 PM ET Deutsche Bank NEW YORK, June 9 (New Ratings) — Analysts at Deutsche Bank issue a "buy" rating on Neurocrine Biosciences, Inc (NBIX). The target price has been raised from $57 to $64. The analysts mention that Neurocrine Biosciences has reported impressive results for its insomnia drug, Indiplon. Deutsche Bank, accordingly, reiterates its projections for eventually higher sales of Indiplon than the present market leader, Ambien.